Ticker Hub
ARWR — AI Analysis & Sentiment
4 recent AI-generated analyses for ARWR. Sentiment and confidence insights updated continuously.
Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026
Arrowhead's positive Phase 1/2a data for ARO-INHBE significantly de-risks a key pipeline asset, supporting its potential in large metabolic disease...
May 27, 2026Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress
Positive clinical data for plozasiran de-risks a key asset and expands its treatable patient population, supporting a bullish outlook for Arrowhead...
May 26, 2026Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)
TGA approval for REDEMPLO in Australia is a key commercial win, expanding market reach for a critical drug. This strengthens the company's revenue ...
May 1, 2026Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe
A positive CHMP opinion significantly advances REDEMPLO towards European market authorization, potentially expanding revenue and market share. This...
Apr 24, 2026